The top analyst upgrades, downgrades and other research calls from Thursday include Adobe, Allergan, American Express, Baker Hughes, Nike, Northern Dynasty Minerals, Sprint and Wayfair.
UnitedHealth, J&J, Nike, and Verizon lifted the DJIA on Tuesday.
General Electric, Nike, Goldman Sachs, and UnitedHealth dragged the DJIA lower on Monday.
The top analyst upgrades, downgrades and other research calls from Thursday include CarMax, DowDuPont, Gilead Sciences, GrubHub, Microsoft, Nike and Western Digital.
Nike, Caterpillar, 3M, and UnitedHealth were Wednesday's top gainer among the Dow 30 stocks.
The week of September 30 has come to an end, and there were several major corporate developments this week that investors simply should not ignore or overlook.
The Dow Jones Industrial Average closed essentially flat on Friday, with Nike and Merck posting the largest losses and Goldman Sachs and Cisco Systems putting up the biggest gains.
After Nike reported its quarterly results late on Tuesday, the investor reaction Wednesday practically wiped out all of its gains so far this year. It doesn't seem like the sports apparel field…
Chris Lange The top analyst upgrades, downgrades and other research calls from Wednesday include Axovant, Carnival, Micron Technology, Nike, SunPower, Vivint Solar and Walgreens.
Nike is schedule to release its most recent quarterly earnings report after the markets close on Tuesday.
Chris Lange 24/7 Wall St. has put together a preview of Nike, Micron Technology and a few other major companies scheduled to report their quarterly results this coming week.
The top analyst upgrades, downgrades and other research calls from Tuesday include Apple, Chesapeake Energy, DowDuPont, Equifax, Gap, Nike, Tesla and Under Armour.
The top analyst upgrades, downgrades and other research calls from Thursday include Apache, Apple, Berkshire Hathaway, eBay, GrubHub, Hess, Nike, Nucor and Wayfair.
The top analyst upgrades, downgrades and other research calls from Tuesday include Alcoa, ADM, Citigroup, Gap, Kroger, Nike, Nucor, Rite Aid, Teva Pharmaceutical and Under Armour.
There is even more pain for the footwear industry, and this includes the retailing shops that rely on shoe sales.
